Novo Nordisk A/S $NVO Shares Sold by Journey Strategic Wealth LLC

Journey Strategic Wealth LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 26.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,955 shares of the company’s stock after selling 2,451 shares during the period. Journey Strategic Wealth LLC’s holdings in Novo Nordisk A/S were worth $480,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Stone House Investment Management LLC acquired a new position in shares of Novo Nordisk A/S in the 1st quarter worth approximately $30,000. NewSquare Capital LLC lifted its stake in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the last quarter. Disciplina Capital Management LLC lifted its stake in Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 297 shares during the last quarter. Dagco Inc. acquired a new position in Novo Nordisk A/S in the first quarter worth $35,000. Finally, Mid American Wealth Advisory Group Inc. bought a new stake in Novo Nordisk A/S during the second quarter valued at $37,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on NVO shares. HSBC set a $70.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, October 1st. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Barclays reiterated an “equal weight” rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Dbs Bank upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. Finally, BNP Paribas Exane raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price on the stock in a research report on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $59.20.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $47.65 on Friday. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $112.52. The company has a market cap of $212.76 billion, a PE ratio of 13.09, a P/E/G ratio of 2.33 and a beta of 0.65. The stock has a 50 day simple moving average of $53.92 and a 200-day simple moving average of $60.33. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.74 billion for the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.